Villanueva A. Hepatocellular carcinoma [J]. N Engl J Med. 2019;380(15):1450–62.

Article  CAS  PubMed  Google Scholar 

Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective [J]. Oncologist. 2010;15(Suppl 4):5–13.

Article  PubMed  Google Scholar 

Tian T, Song C, Jiang L, et al. Hepatitis B virus infection and the risk of cancer among the Chinese population [J]. Int J Cancer. 2020;147(11):3075–84.

Article  CAS  PubMed  Google Scholar 

Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, Abdulla M, Abou Rached A, Adda D, Aho I, Akarca U. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study [J]. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.

Article  Google Scholar 

Xie D, Shi J, Zhou J, et al. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2023;29(2):206–16.

Article  PubMed  Google Scholar 

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma [J]. Gastroenterology. 2019;156(2):477-91.e1.

Article  PubMed  Google Scholar 

Ayub A, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level [J]. Biomed Res Int. 2013;2013: 810461.

Article  PubMed  PubMed Central  Google Scholar 

Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma [J]. J Hepatol. 2016;64(1 Suppl):S84-s101.

Article  CAS  PubMed  Google Scholar 

Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights [J]. Hepatobiliary Surg Nutr. 2020;9(4):452–63.

Article  PubMed  PubMed Central  Google Scholar 

Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B [J]. Clin Mol Hepatol. 2020;26(3):261–79.

Article  PubMed  PubMed Central  Google Scholar 

Yang Y, Hsu PJ, Chen YS, et al. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism [J]. Cell Res. 2018;28(6):616–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu ZX, Li LM, Sun HL, et al. Link between m6A modification and cancers [J]. Front Bioeng Biotechnol. 2018;6:89.

Article  PubMed  PubMed Central  Google Scholar 

Shulman Z, Stern-Ginossar N. The RNA modification N(6)-methyladenosine as a novel regulator of the immune system [J]. Nat Immunol. 2020;21(5):501–12.

Article  CAS  PubMed  Google Scholar 

Li Y, Xiao J, Bai J, et al. Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types [J]. Mol Cancer. 2019;18(1):137.

Article  PubMed  PubMed Central  Google Scholar 

Chen M, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 [J]. Hepatology. 2018;67(6):2254–70.

Article  CAS  PubMed  Google Scholar 

Li Q, Ni Y, Zhang L, et al. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation [J]. Signal Transduct Target Ther. 2021;6(1):76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Huang S, Zhuang H, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation [J]. Oncogene. 2020;39(23):4507–18.

Article  CAS  PubMed  Google Scholar 

Wang S, Chai P, Jia R, et al. Novel insights on m(6)A RNA methylation in tumorigenesis: a double-edged sword [J]. Mol Cancer. 2018;17(1):101.

Article  PubMed  PubMed Central  Google Scholar 

Bao X, Shi R, Zhao T, et al. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma [J]. Mol Oncol. 2020;14(5):917–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis [J]. J Clin Oncol. 2008;26(8):1364–70.

Article  PubMed  Google Scholar 

Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking [J]. Bioinformatics. 2010;26(12):1572–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles [J]. Nat Methods. 2015;12(5):453–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic Acids Res. 2015;43(7): e47.

Article  PubMed  PubMed Central  Google Scholar 

Zhang B, Wu Q, Li B, et al. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer [J]. Mol Cancer. 2020;19(1):53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kostyusheva A, Brezgin S, Glebe D, et al. Host-cell interactions in HBV infection and pathogenesis: the emerging role of m6A modification [J]. Emerg Microbes Infect. 2021;10(1):2264–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang W, Chen S, Liu J, et al. Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk [J]. J Cell Biochem. 2019;120(4):5510–8.

Article  CAS  PubMed  Google Scholar 

Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions [J]. Cytokine Growth Factor Rev. 1997;8(1):45–62.

Article  CAS  PubMed  Google Scholar 

Luo SM, Tan WM, Deng WX, et al. Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis [J]. World J Gastroenterol. 2005;11(27):4272–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Jin Y, Wan X, et al. SALIS transcriptionally represses IGFBP3/Caspase-7-mediated apoptosis by associating with STAT5A to promote hepatocellular carcinoma [J]. Cell Death Dis. 2022;13(7):642.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang LJ, Tang Q, Wu J, et al. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells [J]. J Exp Clin Cancer Res. 2016;35:59.

Article  PubMed  PubMed Central  Google Scholar 

Xu Y, Zheng Y, Liu H, et al. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction [J]. Int J Oncol. 2017;51(3):791–800.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gutschner T, Hämmerle M, Pazaitis N, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma [J]. Hepatology. 2014;59(5):1900–11.

Article  CAS  PubMed  Google Scholar 

Liu Y, Guo Q, Yang H, et al. Allosteric regulation of IGF2BP1 as a novel strategy for the activation of tumor immune microenvironment [J]. ACS Cent Sci. 2022;8(8):1102–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Z, Du Y, Zhao X, et al. Diagnostic, therapeutic, and prognostic value of the ma writer complex in hepatocellular carcinoma [J]. Front Cell Dev Biol. 2022;10: 822011.

Article  PubMed  PubMed Central  Google Scholar 

Lu M, Wu J, Hao Z-W, et al. Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress [J]. Hepatology. 2018;68(1):317–32.

Article  CAS  PubMed  Google Scholar 

Huang H, Weng H, Chen J. mA modification in coding and non-coding RNAs: roles and therapeutic implications in cancer [J]. Cancer Cell. 2020;37(3):270–88.

Article  CAS  PubMed  PubMed Central